It is prudent for trainers to explain all potential risks to new clients, especially those who have never undertaken serious physical activity and may be significantly deconditioned
Recent clinical data show semaglutide 2.4 mg achieved 14.9% mean weight loss at 68 weeks in STEP 1, while tirzepatidewhich targets dual GLP-1 and GIP receptorsproduces 2027% weight loss in comparable trials, yet individual outcomes vary significantly based on genetic predispositions in appetite and energy metabolism pathways
Its quick implementation bypasses complex bureaucracy, enabling rapid transformation
M., Antony, S
What GLP-1 medications might change (and why it matters for pills) GLP1 receptor agonists affect the gut in ways that are central to how they work: they can slow gastric emptying and often cause nausea, sometimes vomiting, and sometimes diarrhea
Owners of dogs may report unilateral or bilateral lameness or paresis/paralysis, toe dragging, low tail or neck carriage, difficulties with rising, sitting or lying down, reluctance to jump or climb, urinary or faecal incontinence, and hyperesthesia or self-mutilation [11]